Lipoprotein Lipase/LPL Antibody

Western Blot: Lipoprotein Lipase/LPL Antibody [NBP1-50735] - Analysis of LPL with lysate from rat kidney (Lane 1) and 3T3 cells (Lane 2).

Product Discontinued

Lipoprotein Lipase/LPL Antibody Summary

• Immunogen: Synthetic peptide surrounding amino acid 427 of rat PLP (AAH81836.1).
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: LPL
• Purity: Affinity purified

Applications/Dilutions

• Dilutions:
  • Western Blot
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.2), 30% glycerol, 0.5% BSA
• Preservative: 0.01% Thimerosal
• Concentration: 0.5 mg/ml
• Purity: Affinity purified

Alternate Names for Lipoprotein Lipase/LPL Antibody

• EC 3.1.1
• HDLCQ11
• LIPD
• LIPDEC 3.1.1.34
• Lipoprotein Lipase
• LPL

Background

LPL, also known as Lipoprotein lipase, is a 475 amino acid that is 53 kDa, is a vascular lipase, but not synthesized in endothelial cells. It is anchored to the capillary endothelium by proteoglycans and acts as a catalyzer of triglycerides hydrolysis to release free fatty acids into the circulation and initiates the processing of triglyceride-rich lipoproteins such as chylomicrons and VLDL. It is being studied for its involvement in 150+ diseases and disorders including high density lipoprotein cholesterol level qtl 11, hyperlipoproteinemia, lipoprotein lipase deficiency, familial lipoprotein lipase deficiency, hyperlipoproteinemia type v, lipase deficiency combined, hyperlipoproteinemia type iii, glycogen storage disease, hyperlipidemia, hypertriglyceridemia, glucose intolerance, cetp deficiency, hypertension, fatty liver, nephrotic syndrome, kidney failure, and myocardial infarction. This protein has been shown to interact with 50 proteins including COPS6, PTPN4, RPL18A, ASCC2, KIAA1377 in developmental biology, transcriptional regulation of white adipocyte differentiation, lipid digestion, mobilization, and transport, metabolism, lipoprotein metabolism, glycerolipid metabolism, PPAR signaling pathway, and Alzheimer's disease pathways.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

⚠ WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause reproductive toxicity with developmental effects.  For more information go to www.P65Warnings.ca.gov.

Publications for Lipoprotein Lipase/LPL Antibody (NBP1-50735)(1)

Publication using NBP1-50735

• Zhang Y, Cui Y, Wang XL et al. PPARa/gamma agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats Cytokine. 2015-07-17 [PMID: 26194065] (WB, Rat)

Bioinformatics

• Gene Symbol: LPL
• Entrez:
  • 4023(Human)
  • 16956(Mouse)
  • 24539(Rat)
• Uniprot:
  • AAH81836.1(Rat)